Group 1 - Jicheng Electronics won a total of 15 bids from the State Grid Corporation, with a total bid amount of approximately 215 million yuan, accounting for 8.27% of the company's projected revenue for 2024 [2] - Jianmin Group's chemical generic drug, Ambrutoro Oral Solution, has been approved for market launch by the National Medical Products Administration, aimed at treating cough and wheezing caused by chronic bronchitis and emphysema [3] - Taiji Industry's subsidiary plans to transfer accounts receivable not exceeding 85 million USD to optimize cash flow, with an expected service fee of approximately 285,000 USD [4] Group 2 - Nanjing Pharmaceutical's subsidiary plans to invest 398 million yuan in a modern pharmaceutical logistics expansion project, with a construction period of approximately 35 months [5] - Ruili Kemi received a development notification from a well-known domestic flying car company to supply core components [6] - Ding Tong Technology announced that several executives plan to reduce their holdings by a total of no more than 45,300 shares, representing about 0.032% of the total share capital [7][8] Group 3 - Ninghu Expressway's subsidiary plans to invest no more than 9.033 billion yuan in the construction of the Nanyang Yangtze River Bridge South Connection Project [10] - Wuliangye announced a mid-term profit distribution plan for 2025, proposing a cash dividend of 25.78 yuan per 10 shares, totaling approximately 10 billion yuan [12] - Beixin Road and Bridge's subsidiary won a bid for a project worth 180 million yuan [14] Group 4 - Minhe Livestock reported a 7.75% month-on-month increase in sales revenue from commodity chick sales in November [15] - Xuelong Group plans to invest 100 million yuan to establish a wholly-owned subsidiary for vertical integration in the aluminum and magnesium technology sector [16] - Shengnong Development reported a 15.77% year-on-year increase in sales revenue in November, with significant growth in both poultry and processed meat products [17] Group 5 - Xingyu Co., Ltd. plans to repurchase shares worth 200 million to 300 million yuan for employee stock ownership plans [18] - Quan Chai Power intends to use 50 million yuan of idle funds to purchase structured deposit products [19] - Shibei High-tech appointed Zhao Junhong as the new deputy general manager [20] Group 6 - Fuan Pharmaceutical's subsidiary received a drug registration certificate for injectable isavuconazole, expanding its anti-infection product line [21] - Xiaoming Co. reported a 49.73% year-on-year decline in chicken product sales revenue in November [22] - Baiao Chemical adjusted its share repurchase price ceiling to no more than 48.95 yuan per share [23] Group 7 - Hefei China reported a 26.02% year-on-year decline in consolidated revenue for the first 11 months [24] - Laimei Pharmaceutical's subsidiary received medical device registration certificates for two endoscope products [25][26] - Xiantan Co. reported an 11.63% year-on-year increase in chicken product sales revenue in November [27] Group 8 - Qilin Security received government subsidies totaling 5.4014 million yuan [28] - Blue Sky Gas's controlling shareholder's 30.9134 million shares were judicially frozen, accounting for 4.33% of the total share capital [29] - Tieke Railway signed a contract for high-speed railway fasteners worth 654 million yuan, accounting for 41.08% of the company's projected revenue for 2024 [30] Group 9 - David Medical's electric surgical table received a medical device registration certificate [31] - Zhendong Pharmaceutical's affiliate's core product new drug application was accepted by the CDE [32] - Shanghai Pharmaceutical's apple acid sitagliptin tablet application for market approval was granted by the National Medical Products Administration [33] Group 10 - Nanjiao Food reported a 1.14% year-on-year increase in consolidated revenue for November [34]

大连百傲化学股份有限公司 关于调整回购股份价格上限的公告 本次调整回购股份价格上限属于董事会审议权限范围，无需提交公司股东 会审议。 一、 回购股份的基本情况 大连百傲化学股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开的 第五届董事会第十二次会议，审议通过了《关于以集中竞价交易方式回购公司股 份方案的议案》，同意公司以自有或自筹资金通过集中竞价交易方式回购公司股份， 用于员工持股计划或股权激励。回购股份价格为不超过人民币 44.94 元/股；回购 股份的资金总额不低于人民币 20,000 万元（含），不超过人民币 40,000 万元（含）； 回购期限为自公司董事会审议通过本次回购股份方案之日起 12 个月内。 因公司实施 2024 年年度权益分派，本次回购股份方案的回购股份价格上限由 不超过人民币 44.94 元/股调整为不超过人民币 31.67 元/股。 证券代码：603360 证券简称：百傲化学 公告编号：2025-090 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 鉴于公司股票 ...

每经AI快讯，12月10日，百傲化学（603360）(603360.SH)公告称，鉴于公司股票价格上涨，原回购股 份价格上限31.67元/股已低于市场价，公司决定将回购股份价格上限调整为不超过48.95元/股。该调整 符合相关法律法规，不影响公司经营和财务状况，旨在保障回购方案顺利实施。此次调整无需提交股东 会审议。 ...

人民财讯12月10日电，百傲化学（603360）12月10日公告，公司将回购股份价格上限调整至不超过 48.95元/股。公司此前披露拟2亿元至4亿元回购股份用于员工持股计划或股权激励。回购股份价格为不 超过44.94元/股。后因实施2024年年度权益分派，将回购股份价格上限由不超过44.94元/股调整为不超 过31.67元/股。 ...

百傲化学公告，回购股份价格上限由不超过人民币48.95元/股调整为不超过48.95元/股。 ...

百傲化学公告称，公司于2025年12月10日召开董事会，审议通过调整回购股份价格上限的议案。调整前 上限为不超31.67元/股，调整后不超48.95元/股，该调整属董事会权限，无需股东会审议。截至公告披 露日，公司累计回购股份819.78万股，占总股本1.16%，回购资金总额1.99亿元。除价格上限外，回购 其他事项不变，公司将按规推进回购并及时披露进展。 ...

| 交易日期 | 证券简称 | 证券代码 | 成交价(元) 成交金额[万元) 成交量(*) 买入营业部 | | | 卖出营业部 | 是否为专场 | | --- | --- | --- | --- | --- | --- | --- | --- | | 025-12-09 | 百傲化学 | 603360 | 30.25 544.5 發開正落起過程度 | - 18 | 药品素繁體製露 | | ка | 12月9日，百傲化学大宗交易成交18万股，成交额544.5万元，占当日总成交额的0.83%，成交价30.25 元，较市场收盘价34.7元折价12.82%。 ...

证券代码：603360 证券简称：百傲化学 公告编号：2025-089 大连百傲化学股份有限公司 关于以集中竞价方式回购股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/4/25 | | --- | --- | | 回购方案实施期限 | 董事会审议通过后 12 个月 | | 预计回购金额 | 20,000万元~40,000万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 8,188,800股 | | 累计已回购股数占总股本比例 | 1.16% | | 累计已回购金额 | 198,660,918.72元 | | 实际回购价格区间 | 19.58元/股~31.66元/股 | 截至 2025 年 11 月 30 日，公司通过集中竞价方式累计回购公司股份 8,188,800 股，已回购股份占公司总股本的比例为 1.16%，回购的最高价为人民币 ...

Core Viewpoint - The company announced a share repurchase plan aimed at utilizing 200 to 400 million yuan for employee stock ownership plans or equity incentives, with a maximum repurchase price of 31.67 yuan per share over a 12-month period [1] Group 1 - The company plans to repurchase shares starting from April 24, 2025, with a budget of 200 to 400 million yuan [1] - As of November 2025, the company has repurchased 2.5281 million shares, accounting for 0.36% of the total share capital, at a cost of 78.9848 million yuan [1] - By November 30, 2025, the cumulative repurchase reached 8.1888 million shares, representing 1.16% of the total share capital, with a total expenditure of 199 million yuan [1]

Core Viewpoint - Baiao Chemical is undergoing a significant transformation by binding key personnel through equity transfer, aiming to enhance its integration with the semiconductor business and drive long-term growth [1][5]. Equity Transfer Details - On November 26, Baiao Chemical announced that its two major shareholders plan to transfer a total of 10% equity to Liu Hongjun [2]. - After the transaction, Liu Hongjun will become a significant shareholder with over 5% ownership and will be appointed as a director and co-general manager of Baiao Chemical [3][5]. - The total transaction amount is approximately 1.986 billion yuan, with a share price of 28.12 yuan, representing an 11% discount compared to the closing price of 31.72 yuan on November 25 [4]. Business Transformation - Baiao Chemical has been a leader in the industrial biocide sector for over 20 years, but it has faced growth challenges in recent years [3][7]. - In 2024, the company began its cross-industry transformation by investing 700 million yuan to gain control of Suzhou Xinhuilian Semiconductor Technology Co., Ltd., marking its entry into the semiconductor field [3][8]. - The company aims to create a dual business model of chemicals and semiconductors, with Liu Hongjun playing a crucial role in this transition [7][9]. Financial Performance - Baiao Chemical's revenue from 2021 to 2024 showed fluctuations, with revenues of 1.006 billion yuan, 1.257 billion yuan, 1.066 billion yuan, and 1.312 billion yuan, while net profits were 250 million yuan, 403 million yuan, 328 million yuan, and 345 million yuan respectively [7]. - In the first three quarters of 2025, the company reported revenues of 1.056 billion yuan and a net profit of 125 million yuan, reflecting a year-on-year change of 17.88% and -50.83% respectively [7]. Semiconductor Business Outlook - Xinhuilian, established in 2019, focuses on semiconductor equipment and achieved revenues of 543 million yuan in 2024, a 215.75% increase, with a net profit of 97 million yuan, a 370.82% increase [8][9]. - Liu Hongjun has committed to achieving a minimum net profit of 1 billion yuan, 1.5 billion yuan, and 2.5 billion yuan for Xinhuilian from 2024 to 2026, totaling at least 5 billion yuan [9].